Suppr超能文献

皮肤恶性黑素瘤中的蛋白酶:作为生物标志物和治疗靶点的相关性。

Proteases in cutaneous malignant melanoma: relevance as biomarker and therapeutic target.

机构信息

Institute of Anatomy, University Tübingen, Österbergstr. 3, 72074 Tübingen, Germany.

出版信息

Cell Mol Life Sci. 2010 Dec;67(23):3947-60. doi: 10.1007/s00018-010-0469-5. Epub 2010 Aug 5.

Abstract

Cutaneous malignant melanoma is the most aggressive skin cancer. It is also the most rapidly spreading cancer in terms of worldwide incidence. Although it is detected by simple inspection and can be relatively easily removed or treated, differential diagnosis to other melanocytic lesions, lack of prognostic markers, and no efficient treatment of advanced melanoma pose problems. Detection and targeting of proteases may represent a useful tool since they play a role in tumor cell metabolism, invasion, angiogenesis and metastasis. This review gives an overview of the role of proteases in development and progression of cutaneous malignant melanoma. In addition, regulation, activation, and interaction of proteases and their inhibitors are explained for tumors in general. The potential use of proteases as differential markers for melanoma mimicking melanocytic lesions, as biomarkers in tissues, and as prognostic serum markers is discussed. Current and future possibilities to target tumor proteases in therapy are presented.

摘要

皮肤恶性黑素瘤是最具侵袭性的皮肤癌。就全球发病率而言,它也是扩散最快的癌症。尽管它可以通过简单的检查发现,并且相对容易切除或治疗,但与其他黑素细胞病变的鉴别诊断、缺乏预后标志物以及对晚期黑色素瘤的有效治疗仍存在问题。蛋白酶的检测和靶向可能是一种有用的工具,因为它们在肿瘤细胞代谢、侵袭、血管生成和转移中发挥作用。本综述概述了蛋白酶在皮肤恶性黑素瘤的发生和发展中的作用。此外,还解释了一般肿瘤中蛋白酶及其抑制剂的调节、激活和相互作用。讨论了蛋白酶作为黑素瘤模拟黑素细胞病变的差异标志物、组织中的生物标志物以及预后血清标志物的潜在用途。还介绍了目前和未来在治疗中靶向肿瘤蛋白酶的可能性。

相似文献

1
Proteases in cutaneous malignant melanoma: relevance as biomarker and therapeutic target.
Cell Mol Life Sci. 2010 Dec;67(23):3947-60. doi: 10.1007/s00018-010-0469-5. Epub 2010 Aug 5.
2
Proteases in cutaneous melanoma.
Ann Med. 1998 Oct;30(5):431-42. doi: 10.3109/07853899809002484.
3
Pathology of malignant melanoma, including new markers and techniques in diagnosis and prognosis.
Curr Opin Oncol. 1996 Mar;8(2):143-51. doi: 10.1097/00001622-199603000-00012.
5
Serum matrix metalloproteinase-2 as a prognostic marker in advanced cutaneous melanoma.
Acta Oncol. 2000;39(7):877-9. doi: 10.1080/028418600750063659.
6
Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions.
J Pathol. 2001 Jun;194(2):194-200. doi: 10.1002/1096-9896(200106)194:2<194::AID-PATH851>3.0.CO;2-S.
9
Markers of melanocytic tumour progression.
J Pathol. 1998 Dec;186(4):340-2. doi: 10.1002/(SICI)1096-9896(199812)186:4<340::AID-PATH182>3.0.CO;2-K.

引用本文的文献

2
Cell jamming in a collagen-based interface assay is tuned by collagen density and proteolysis.
J Cell Sci. 2023 Dec 1;136(23). doi: 10.1242/jcs.260207. Epub 2023 Dec 15.
3
Dipeptide-Derived Alkynes as Potent and Selective Irreversible Inhibitors of Cysteine Cathepsins.
J Med Chem. 2023 Mar 23;66(6):3818-3851. doi: 10.1021/acs.jmedchem.2c01360. Epub 2023 Mar 3.
4
Eyes absent gene (EYA1) is a pathogenic driver and a therapeutic target for melanoma.
Oncotarget. 2017 Sep 27;8(62):105081-105092. doi: 10.18632/oncotarget.21352. eCollection 2017 Dec 1.
6
Matrix metalloproteinase-3 gene promoter polymorphisms: A potential risk factor for pelvic organ prolapse.
Biomed Rep. 2016 Sep;5(3):337-343. doi: 10.3892/br.2016.736. Epub 2016 Aug 3.
7
Vitronectin and dermcidin serum levels predict the metastatic progression of AJCC I-II early-stage melanoma.
Int J Cancer. 2016 Oct 1;139(7):1598-607. doi: 10.1002/ijc.30202. Epub 2016 Jun 11.
9
Cysteine cathepsins: their role in tumor progression and recent trends in the development of imaging probes.
Front Chem. 2015 Jun 23;3:37. doi: 10.3389/fchem.2015.00037. eCollection 2015.
10
Investigation of the role of polymorphism in cutaneous malignant melanoma - a preliminary study.
Biotechnol Biotechnol Equip. 2014 Sep 3;28(5):904-910. doi: 10.1080/13102818.2014.947694. Epub 2014 Nov 13.

本文引用的文献

1
Granzymes in cancer and immunity.
Cell Death Differ. 2010 Apr;17(4):616-23. doi: 10.1038/cdd.2009.206. Epub 2010 Jan 15.
3
Avoiding spam in the proteolytic internet: future strategies for anti-metastatic MMP inhibition.
Biochim Biophys Acta. 2010 Jan;1803(1):95-102. doi: 10.1016/j.bbamcr.2009.09.016. Epub 2009 Oct 1.
5
HER2 breast cancer therapies: a review.
Biologics. 2009;3:289-301. Epub 2009 Jul 13.
6
Extracellular proteases as targets for drug development.
Curr Protein Pept Sci. 2009 Aug;10(4):297-307. doi: 10.2174/138920309788922207.
7
Utility of adjuvant systemic therapy in melanoma.
Ann Oncol. 2009 Aug;20 Suppl 6(Suppl 6):vi30-4. doi: 10.1093/annonc/mdp250.
8
Stromal expression of MMP-13 is required for melanoma invasion and metastasis.
J Invest Dermatol. 2009 Nov;129(11):2686-93. doi: 10.1038/jid.2009.130. Epub 2009 Jun 11.
9
Maspin expression, angiogenesis, prognostic parameters, and outcome in malignant melanoma.
J Am Acad Dermatol. 2009 May;60(5):758-66. doi: 10.1016/j.jaad.2009.01.018.
10
Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma.
Nat Genet. 2009 May;41(5):518-20. doi: 10.1038/ng.340. Epub 2009 Mar 29.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验